Hans-Peter Kiem, M.D., Ph.D.

Vice President


Dr. Kiem is a physician-scientist studying hematopoietic stem cell (HSC) biology, transplantation, immunotherapy and gene therapy/genome editing. He's also a trained and clinically active oncologist seeing patients on the marrow transplant and immunotherapy services. Dr. Kiem is currently the Stephanus Family Endowed Chair for Cell and Gene Therapy at Fred Hutchinson Cancer Research Center.

As a fellow and junior faculty, Dr. Kiem was part of the Fred Hutch team developing nonmyeloablative transplantation. As an independent investigator, he developed a research laboratory and program focusing on the biology and transplantation of HSCs and the development of novel technologies to expand and/or genetically modify HSCs or T cells for the treatment of cancer, HIV, and genetic diseases such as Fanconi anemia, severe combined immunodeficiency, and hemoglobinopathies. Recent studies in the lab include CRISPR/Cas-based genome editing of HSCs for hemoglobinopathies and in vivo gene therapy approaches with viral vectors and nanoparticles with the goal to make gene therapy also more accessible in resource-limited settings in the world. Dr. Kiem has extensive experience training students and postdoctoral fellows and has mentored more than 70 trainees in his lab over the past 25 years. He has been the sponsor and PI of several clinical stem cell gene therapy studies. Dr. Kiem served four years as a member of the Recombinant DNA Advisory Committee and one year as Chair and he is therefore very familiar with most gene therapy  and genome editing applications and any ethical considerations. Over the past five years, Dr. Kiem has also served as a member and chair on the ASGCT and ASH Stem Cell Committees.

2021

ASGCT 24th Annual Meeting

May 12-15, 2021